Browse
Explore conditions, clinical trials, and the organisations running them.
Up to: Toxic or drug-related embryofetopathy
Aminopterin/methotrexate embryofetopathy
Aminopterin/Methotrexate embryofetopathy is a syndrome of developmental anomalies characterized by growth deficiency, facial dysmorphism and skull, limb and neural defects secondary to maternal exposure to aminopterin or methotrexate (MTX) during pregnancy.
This condition has no sub-types.